Clinical Trial Update: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Takeda-sponsored Phase 3 clinical trial evaluating mezagitamab in adults with chronic primary immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Mezagitamab (mezagitamab)

Snippet

Sponsor: Takeda | Conditions: Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Status: RECRUITING